186 related articles for article (PubMed ID: 18829557)
1. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM
Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
3. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.
Theys J; Pennington O; Dubois L; Anlezark G; Vaughan T; Mengesha A; Landuyt W; Anné J; Burke PJ; Dûrre P; Wouters BG; Minton NP; Lambin P
Br J Cancer; 2006 Nov; 95(9):1212-9. PubMed ID: 17024128
[TBL] [Abstract][Full Text] [Related]
4. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic tumour targeting using clostridial spores.
Minton NP; Mauchline ML; Lemmon MJ; Brehm JK; Fox M; Michael NP; Giaccia A; Brown JM
FEMS Microbiol Rev; 1995 Oct; 17(3):357-64. PubMed ID: 7576773
[TBL] [Abstract][Full Text] [Related]
6. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.
Heap JT; Theys J; Ehsaan M; Kubiak AM; Dubois L; Paesmans K; Van Mellaert L; Knox R; Kuehne SA; Lambin P; Minton NP
Oncotarget; 2014 Apr; 5(7):1761-9. PubMed ID: 24732092
[TBL] [Abstract][Full Text] [Related]
7. A mammalianized synthetic nitroreductase gene for high-level expression.
Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ
BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451
[TBL] [Abstract][Full Text] [Related]
8. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
9. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Liu SC; Minton NP; Giaccia AJ; Brown JM
Gene Ther; 2002 Feb; 9(4):291-6. PubMed ID: 11896468
[TBL] [Abstract][Full Text] [Related]
10. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF
Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
13. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
14. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
[TBL] [Abstract][Full Text] [Related]
15. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
16. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Fox ME; Lemmon MJ; Mauchline ML; Davis TO; Giaccia AJ; Minton NP; Brown JM
Gene Ther; 1996 Feb; 3(2):173-8. PubMed ID: 8867865
[TBL] [Abstract][Full Text] [Related]
17. The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach.
Ball P; Thompson E; Anderson S; Gwenin V; Ashoorzadeh A; Smaill J; Gwenin C
Biosci Rep; 2023 Apr; 43(4):. PubMed ID: 37067816
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
19. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
20.
Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
